- Home
- DSGX vs CORT Comparison
DSGX vs CORT Comparison
Compare DSGX & CORT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DSGX
- CORT
- Stock Information
- Founded
- DSGX 1981
- CORT 1998
- Country
- DSGX Canada
- CORT United States
- Employees
- DSGX N/A
- CORT N/A
- Industry
- DSGX Computer Software: Prepackaged Software
- CORT Biotechnology: Pharmaceutical Preparations
- Sector
- DSGX Technology
- CORT Health Care
- Exchange
- DSGX Nasdaq
- CORT Nasdaq
- Market Cap
- DSGX 8.8B
- CORT 8.1B
- IPO Year
- DSGX 1999
- CORT N/A
- Fundamental
- Price
- DSGX $99.22
- CORT $71.38
- Analyst Decision
- DSGX Buy
- CORT Strong Buy
- Analyst Count
- DSGX 7
- CORT 4
- Target Price
- DSGX $125.14
- CORT $142.00
- AVG Volume (30 Days)
- DSGX 409.6K
- CORT 1.4M
- Earning Date
- DSGX 06-04-2025
- CORT 07-28-2025
- Dividend Yield
- DSGX N/A
- CORT N/A
- EPS Growth
- DSGX 17.84
- CORT 8.36
- EPS
- DSGX 1.65
- CORT 1.14
- Revenue
- DSGX $668,391,000.00
- CORT $685,446,000.00
- Revenue This Year
- DSGX $11.87
- CORT $35.85
- Revenue Next Year
- DSGX $13.36
- CORT $35.22
- P/E Ratio
- DSGX $59.06
- CORT $62.59
- Revenue Growth
- DSGX 13.74
- CORT 30.93
- 52 Week Low
- DSGX $90.61
- CORT $28.10
- 52 Week High
- DSGX $124.31
- CORT $117.33
- Technical
- Relative Strength Index (RSI)
- DSGX 35.91
- CORT 48.38
- Support Level
- DSGX $97.30
- CORT $69.60
- Resistance Level
- DSGX $100.88
- CORT $73.13
- Average True Range (ATR)
- DSGX 2.62
- CORT 3.50
- MACD
- DSGX -1.05
- CORT -0.18
- Stochastic Oscillator
- DSGX 10.33
- CORT 24.77
About DSGX Descartes Systems Group Inc. (The)
Descartes Systems Group provides a software solution that allows users in the shipping industry to communicate with one another. Its core product is the Global Logistics Network, which is best understood as transaction-driven. Descartes charges clients to send/receive messages, data, and documents on the GLN. Customers typically contract for a monthly minimum over a multiyear period. The GLN platform allows Descartes to upsell additional software modules as well, typically provided via a software-as-a-service model.
About CORT Corcept Therapeutics Incorporated
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic and neuropsychiatric disorders by modulating the effect of the hormone cortisol. The company's compounds are being evaluated in clinical trials as potential treatments for a variety of serious disorders - hypercortisolism, advanced ovarian cancer, prostate cancer, ALS, and MASH.